All In Biotech

Drug Trial Radar · NCT03856827

A Study of IW-6463 in Healthy Volunteers

A Phase 1 Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics of IW-6463 When Administered to Healthy Volunteers as Single Ascending Doses, as Multiple Ascending Doses, and Under Fed Versus Fasting Conditions

Last checked: Nov 19, 2026Latest source record: Aug 16, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 110 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

110

Actual

Start

Feb 6, 2019

Primary completion

Oct 22, 2019

Study completion Oct 22, 2019

Sponsor

Lead sponsor
Tisento TherapeuticsIndustry
Sponsor type
Industry
First posted
Feb 27, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Sequential
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Other
FDA-regulated drug
Yes
Who can join
All sexes
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

Stage 1: To assess the safety and tolerability of single-ascending-dose levels of IW-6463 tablets when administered orally to healthy subjects Stage 2: To assess the safety and tolerability of multiple-ascending-dose levels of IW-6463 tablets administered orally to healthy subjects Stage 3: To assess the safety and tolerability of a single dose of IW-6463 when administered to health subjects in fed vs fasted states and explore the effects of food on IW-6463 pharmacokinetics (PK)

Conditions

  • Other

Interventions

  • IW-6463Drug

    IW-6463 Tablet

  • Matching PlaceboDrug

    Matching Placebo Tablet

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. After single ascending doses, number of subjects with treatment-emergent adverse events (TEAEs) in the IW-6463 dose-level cohorts vs the (pooled) placebo group.Time frame: Up to 9 days
  2. After multiple ascending doses, number of subjects with TEAEs in the IW-6463 dose-level cohorts vs the (pooled) placebo group.Time frame: Up to 32 days
  3. After a single dose, number of subjects with TEAEs in the fed vs fasted dosing periodTime frame: Up to 28 days
  4. Plasma concentration of IW-6463 after single-dose administration under fed vs fasted conditionsTime frame: Up to 21 days

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Centre for Human Drug Research

    Leiden, Netherlands

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.